Menu

Recent Interviews

Alex Kent, Managing Director, Aspermont Limited

Alex Kent
Managing Director | Aspermont Limited
613 - 619 Wellington Street, WA, 6000 Perth (AUS)

Corporate@aspermont.com

+61 8 6263 9100

Aspermont shows the success of digitalization - Alex Kent has an agenda


Jim Payne, CEO, dynaCERT Inc.

Jim Payne
CEO | dynaCERT Inc.
101-501 Alliance Avenue, M6N 2J1 Toronto, Ontario (CAN)

jpayne@dynacert.com

+1 416 766 9691

dynaCERT CEO Jim Payne on attractive hydrogen opportunities


Sebastian-Justus Schmidt, CEO and Founder, Enapter AG

Sebastian-Justus Schmidt
CEO and Founder | Enapter AG
Ziegelhäuser Landstraße 1, 69120 Heidelberg (D)

info@enapterag.de

Enapter AG CEO and founder Sebastian-Justus Schmidt on the future of hydrogen


21. January 2020 | 13:48 CET

Aphria, Cronos Group, EXMceuticals - it is a buyers' market!

  • Cannabis
Photo credits: pixabay.com

The shares of numerous well-known and unknown cannabis companies have had a dramatic year 2019. Price losses of over 50% are not uncommon. What costs only half today may have become twice as attractive. Due to the large number of cannabis companies listed on the stock exchange, this is the time for investors who are planning a new investment.

time to read: 1 minutes by Mario Hose


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Emergence of a market

Among the well-known companies in the cannabis industry are Aphria, Aurora Cannabis, Canopy Growth and also Cronos Group. In the past year new names also came onto the market, but in connection with the price losses of the big players they received little attention or suffered collateral damage.

So it may be more worthwhile than ever to put newcomers like EXMceuticals on the watch list. The cannabis market is in the development phase and in the course of this, changes in legislation around the globe as well as in the product range will be visible.

Education and pioneering work

The large companies such as Aphria and Cronos Group have done a lot of pioneering work in their home country Canada and in many other regions around the globe in recent years. Although the cannabis plant is an ancient remedy, the worldwide wave of legalization has made extensive educational work necessary for politicians, medicine and potential customers.

The confidence in new therapies does not come overnight and it requires a lot of understanding and patience to build a market for a new product universe.

EXMceuticals is building a team of experts

Compared to Aphria and Cronos Group, EXMceuticals is still in a development phase. CEO Jonathan Summers has announced numerous new additions to the team in recent months to develop the operational business with experts who have both experience and an established network.

Although EXMceuticals is headquartered in Canada, due to a shell acquisition, the operational business is located in Europe and Africa.

Entry level at low

Aphria is valued at CAD 1.8 billion market capitalization at a stock market price of CAD 7.02. The shares of Cronos Group changed hands most recently at CAD 11.27 and are valued at CAD 3.9 billion. EXMceuticals is still a lightweight with a market capitalization of 16.5 million CAD at a price of 0.45 CAD, but there is still the opportunity to enter at a low valuation level in order to profit from further developments. As is well known, the profit lies in purchasing.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

07. December 2020 | 10:01 CET | by André Will-Laudien

EXMceuticals, Aurora, Xphyto Therapeutics - Cannabis 2.0 and Psilocybin!

  • Cannabis

The North American Cannabis Index has brought itself back to life in October! The index lost 80% since the beginning of 2019, but it's going up again with the survivors of the industry. Overall, the capitalization of the sector has decreased by 85%, with the election of Joe Biden, the second buying wave of purchases is underway. If hemp production was the initial focus, it is now the applications, the achieved market access and new active ingredient combinations. In the slipstream of the therapeutic plant customer, another topic came to the fore that has caused investors' hearts to stutter in recent weeks: the psychedelic drugs in the form of psilocybin. Psilocybin has been used as an entheogen and hallucinogenic drug since prehistoric times. Now the medical applications are being investigated. The trend is already running at full speed, the Canadian brokerage house Canaccord estimates the market volume of all indications that are suitable for treatment with active psychedelic ingredients to be USD 100 billion.

Read

15. July 2020 | 12:23 CET | by Mario Hose

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read

19. May 2020 | 15:02 CET | by Mario Hose

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read